Guidance for Emergent BioSolutions, Inc. (EBS)
Period | Range | Estimate | Revenue Range | Revenue Estimate | Target | Details |
---|---|---|---|---|---|---|
2023 | N/A | N/A | $1.00B – 1.10B | $1.04B | = Maintained | Details |
2023 | N/A | N/A | $1.15B | $1.18B | = Maintained | Details |
2021 | N/A | N/A | $1.95B – 2.05B | $1.93B | = Maintained | Details |
Q3 2021 | N/A | N/A | $1700.00B – 1900.00B | $1.80B | = Maintained | Details |
Q2 2021 | N/A | N/A | $370.00M – 430.00M | $502.30M | Lowered | Details |
2020 | N/A | N/A | $1.50B – 1.60B | $1.39B | Raised | Details |
Q3 2020 | N/A | N/A | $420.00M – 450.00M | $420.20M | Raised | Details |
2019 | N/A | N/A | $1.06B – 1.14B | $1.08B | = Maintained | Details |
Q2 2019 | N/A | N/A | $200.00M – 220.00M | $254.14M | = Maintained | Details |
2018 | N/A | N/A | $715.00M – 755.00M | $706.00M | = Maintained | Details |
2018 | $770.00 – $800.00 | $741.00 | N/A | N/A | = Maintained | Details |
2018 | N/A | N/A | $715.00M – 755.00M | $738.54M | = Maintained | Details |
Q2 2018 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q4 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q3 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q2 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
Q1 2017 | N/A | N/A | N/A | N/A | = Maintained | Details |
2015 | N/A | N/A | $510.00M – 540.00M | N/A | = Maintained | Details |
2014 | N/A | N/A | $440.00M – 460.00M | $443.14M | Raised | Details |
2014 | N/A | N/A | $45.00M – 55.00M | $46.80M | = Maintained | Details |
2013 | N/A | N/A | $290.00M – 310.00M | $314.71M | = Maintained | Details |
2013 | N/A | N/A | $40.00M – 50.00M | $60.00M | Lowered | Details |
2013 | N/A | N/A | $290.00M – 310.00M | $300.60M | = Maintained | Details |
2012 | N/A | N/A | $280.00M – 300.00M | $304.50M | = Maintained | Details |
2012 | N/A | N/A | $60.00M – 70.00M | $78.32M | = Maintained | Details |
2012 | N/A | N/A | $280.00M – 300.00M | $292.99M | = Maintained | Details |
Q2 2012 | N/A | N/A | $70.00M – 80.00M | $76.60M | = Maintained | Details |
2011 | N/A | N/A | $270.00M – 290.00M | $326.68M | = Maintained | Details |